Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Zenas BioPharma, Inc. (NASDAQ:ZBIO) has received a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $43.1429.

Several equities research analysts have weighed in on ZBIO shares. Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright reissued a “buy” rating on shares of Zenas BioPharma in a research note on Tuesday, December 16th. Citigroup boosted their price objective on shares of Zenas BioPharma from $27.00 to $46.00 and gave the stock a “buy” rating in a research report on Tuesday, October 28th. Evercore ISI began coverage on Zenas BioPharma in a report on Wednesday, November 26th. They set an “outperform” rating and a $55.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a research report on Monday, December 29th.

Zenas BioPharma Price Performance

Zenas BioPharma stock opened at $16.08 on Friday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 5.66 and a current ratio of 5.66. The firm has a market cap of $863.17 million, a P/E ratio of -2.27 and a beta of -1.45. The business’s fifty day moving average is $34.94 and its two-hundred day moving average is $24.01. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO) last announced its earnings results on Wednesday, November 12th. The company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.35).

Insider Transactions at Zenas BioPharma

In other news, CEO Leon O. Moulder, Jr. purchased 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were acquired at an average price of $16.38 per share, for a total transaction of $819,000.00. Following the completion of the acquisition, the chief executive officer directly owned 316,155 shares in the company, valued at approximately $5,178,618.90. The trade was a 18.79% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 100,000 shares of company stock valued at $1,639,000 in the last quarter. 16.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Quarry LP boosted its stake in shares of Zenas BioPharma by 34.5% in the 3rd quarter. Quarry LP now owns 1,134 shares of the company’s stock valued at $25,000 after purchasing an additional 291 shares during the last quarter. Russell Investments Group Ltd. bought a new position in Zenas BioPharma in the third quarter valued at approximately $30,000. BNP Paribas Financial Markets boosted its stake in Zenas BioPharma by 120.0% in the third quarter. BNP Paribas Financial Markets now owns 3,146 shares of the company’s stock valued at $70,000 after acquiring an additional 1,716 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Zenas BioPharma by 41.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 9,179 shares of the company’s stock worth $89,000 after acquiring an additional 2,679 shares during the period. Finally, Sei Investments Co. bought a new stake in shares of Zenas BioPharma during the 2nd quarter valued at $118,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.